Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GPTJL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Tras-ALN
|
|||||
| Synonyms |
Trastuzumab-ALN
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Bone metastasis [ICD11:2E03]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Alendronate
|
Payload Info | ||||
| Therapeutic Target |
Farnesyl pyrophosphate synthase (FDPS)
|
Target Info | ||||
| Linker Name |
Bicyclo[6.1.0]nona-4-yne
|
Linker Info | ||||
| Conjugate Type |
To prepare the Tras-ALN conjugate, pClick was used to generate Tras containing an azide functional moiety, followed by reaction with bicyclo[6.1.0]nonyne (BCN)functionalized ALN.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.